Announcement of The Consolidated Financial Report for The 4th Quarter of 2025
2026.3.9
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/03/09 | Time of announcement | 20:06:26 |
| Subject | Announcement of The Consolidated Financial Report for The 4th Quarter of 2025 | ||||
| Date of events | 2026/03/09 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2026/03/09 2.Date of the audit committee approved:2026/03/09 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2025/01/01~2025/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):6,452,948 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):3,720,553 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,703,959 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):2,125,178 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):1,654,704 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):1,559,125 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):6.27 11.Total assets end of the period (thousand NTD):11,348,069 12.Total liabilities end of the period (thousand NTD):3,296,727 13.Equity attributable to owners of parent end of the period (thousand NTD):7,238,410 14.Any other matters that need to be specified:None. |
||||